Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $292.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective raised by Needham & Company LLC from $282.00 to $292.00 in a research note issued to investors on Tuesday morning, Marketbeat reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently commented on JAZZ. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Canaccord Genuity Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $290.00 price objective on the stock. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Royal Bank Of Canada upped their price objective on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Finally, TD Cowen raised their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $272.74.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $256.65 on Tuesday. The firm has a market cap of $16.66 billion, a P/E ratio of 17.70, a P/E/G ratio of 0.23 and a beta of 0.32. Jazz Pharmaceuticals has a 52-week low of $106.65 and a 52-week high of $265.05. The business’s 50-day moving average price is $240.89 and its 200 day moving average price is $209.19. The company has a quick ratio of 1.85, a current ratio of 1.78 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the prior year, the company earned ($8.25) earnings per share. The firm’s revenue was up 15.5% on a year-over-year basis. On average, equities research analysts expect that Jazz Pharmaceuticals will post 21.61 earnings per share for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the sale, the director directly owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 19,098 shares of company stock worth $4,649,786. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cardinal Capital Management lifted its holdings in shares of Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the period. Bessemer Group Inc. boosted its stake in Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after buying an additional 73 shares in the last quarter. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares during the period. Pinnacle Associates Ltd. grew its holdings in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 4.4% in the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 85 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo upgraded Jazz Pharmaceuticals to Buy and raised its price target to $300 from $285, adding to a broadly favorable analyst view. Jazz Pharmaceuticals Receives a Buy from Wells Fargo
• Positive Sentiment: Morgan Stanley raised its price target to $280, while Needham also forecast meaningful appreciation and maintained a bullish stance. JPMorgan separately indicated that the stock could rise, reinforcing investor confidence in JAZZ’s valuation and growth prospects. Morgan Stanley Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz’s second-quarter revenue reached $1.21 billion, exceeding the $1.11 billion consensus estimate and increasing 15.5% year over year. Management raised its 2026 revenue guidance to $4.60 billion-$4.75 billion, supported by strength in its neuroscience and oncology businesses.
• Positive Sentiment: The Xywav-led oxybate franchise continues to post double-digit growth despite generic Xyrem competition, reducing concerns about near-term erosion in Jazz’s core business. Potential FDA approval of Ziihera for first-line gastroesophageal cancer on August 25 also provides an additional catalyst.
• Neutral Sentiment: A valuation comparison with Techne highlights JAZZ as a stock investors are assessing on earnings, growth and relative value metrics, but the article does not represent a new fundamental development for Jazz Pharmaceuticals. JAZZ vs. TECH Which Stock Is the Better Value Option
• Negative Sentiment: Adjusted quarterly EPS of $5.71 missed the $6.18 consensus estimate, which could limit upside if future earnings do not keep pace with revenue growth.
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares worth about $1.52 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by only 1.64%, making it a limited signal of insider concern.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.